Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 120-127

  Xiao, Wenjing ^a   Chen, Xiang ^a   Yang, Li ^a   Mao, Yongqiu ^a   Wei, Yuquan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cationic liposomes; Doxorubicin; FGF mediated; Plasmid

Indexed keywords

DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR; LIPOSOME; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DRUG POTENTIATION; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

EID: 77953364278     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.018     Document Type: Article

References (30)

1. Asanuma K., Moriai R., Yajima T., Yagihashi A., Yamada M., Kobayashi D., Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn. J. Cancer Res. 2000, 91:1204-1209.
2. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee L.W. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001, 19:1444-1454.
3. Chen X., Wang X.H., Wang Y.S., Yang L., Hu J., Xiao W.J., Fu A.F., Cai L.L., Li X., Ye X., Liu Y.L., Wu W.S., Shao X.M., Mao Y.Q., Wei Y.Q., Chen L.J. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J. Control Release 2010, 10.1016/j.jconrel.2010.03.007.
4. Ghera B.B., Perret F., Chevalier Y., Parrot-Lopez H. Novel nanoparticles made from amphiphilic perfluoroalkyl α-cyclodextrin derivatives: Preparation, characterization and application to the transport of acyclovir. Int. J. Pharm. 2009, 375:155-162.
5. Grossman D., Kim P.J., Schechner J.S., Altieri D.C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 2001, 98:635-640.
6. Gu D.L., Gonzalez A.M., Printz M.A., Doukas J., Ying W., D'Andrea M., Hoganson D.K., Curiel D.T., Douglas J.T., Sosnowski B.A., Baird A., Aukerman S.L., Pierce G.F. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. 1999, 59:2608-2614.
7. Hara T., Aramaki Y., Takada S., Koike K., Tsuchiya S. Receptor-mediated transfer of pSV2CAT DNA to a human hepatoblastoma cell line HepG2 using asialofetuin-labeled cationic liposomes. Gene 1995, 159:167-174.
8. Henk J.B., Kristy J.G., Henk M.W.V. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Update 2009, 12:114-126.
9. Janát-Amsbury M.M., Yockman J.W., Lee M., Kern S., Furgeson D.Y., Bikram M., Kim S.W. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol. Ther. 2004, 9:829-836.
10. Kanwar J.R., Shenm W.P., Kanwar R.K., Berg R.W., Krissansen G.W. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. 2001, 93:1541-1552.
11. Kishida T., Asada H., Itokawa Y., Yasutomi K., Shin-Ya M., Gojo S., Cui F., Ueda Y., Yamagishi H., Imanishi J., Mazda O. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous andmetastatic melanomas in mice. Mol. Ther. 2003, 8:738-745.
12. Kleeff J., Fukahi K., Lopez M.E., Friess H., Buchler M.W., Sosnowski B.A., Korc M. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther. 2002, 9:522-532.
13. Liu F., Shollenberger L.M., Huang L. Non-immunostimulatory nonviral vectors. FASEB J. 2004, 18:1779-1781.
14. Nakase M., Inui M., Okumura K., Kamei T., Nakamura S., Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 2005, 4:625-631.
15. Paduano F., Villa R., Pennati M., Folini M., Binda M., Daidone M.G., Zaffaron N. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol. Cancer Ther. 2006, 5:179-186.
16. Peng X.C., Yang L., Yang L.P., Mao Y.Q., Yang H.S., Liu J.Y., Zhang D.M., Chen L.J., Wei Y.Q. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant. J. Exp. Clin. Cancer Res. 2008, 27:46-58.
17. Printz M.A., Gonzalez A.M., Cunningham M., Gu D.L., Ong M., Pierce G.F., Aukerman S.L. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum. Gene Ther. 2000, 11:191-204.
18. Rancourt C., Rogers B.E., Sosnowski B.A., Wang M., Piche A., Pierce G.F., Alvarez R.D., Siegal G.P., Douglas J.T., Curiel D.T. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 1998, 4:2455-2461.
19. Rogers B., Douglas J., Ahlem C., Buchsbaum D., Frincke J., Curiel D. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther. 1997, 4:1387-1392.
20. Salvesen G.S., Duckett C.S. Apoptosis: IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
21. Sawant R.R., Torchilin V.P. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int. J. Pharm. 2009, 374:114-118.
22. Shi P.J., Zuo Y., Qin Z., Shen J., Zhang L., Li Z., Li Y.B., Morsi Y.S. Improved properties of incorporated chitosan film with ethyl cellulose microspheres for controlled release. Int. J. Pharm. 2009, 375:67-74.
23. Takanami I., Imamuma T., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., Kodaira S. Expression of PDGF IGF-II, bFGF and TGF-beta1 in pulmonary adenocarcinoma. Pathol. Res. Pract. 1996, 192:1113-1120.
24. Tan C., Etcuhanas E., Wollner N., Rosen G., Gilladoga A., Showel J., Murphy M.L., Krakoff I.H. Adriamycin-an antitumor antibiotic in the treatment of neoplastic disease. Cancer (Phila.) 1973, 32:9-17.
25. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., Hanahan D., McDonald D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Investig. 1998, 101:1401-1413.
26. Van Heeswijk W.A.R., Stoffer T., Eenick M.J.D., Potman W., Van der Vijgh W.J.F., Van der Poort J., Pinedo H.M., Lelieveld P., Feijen J. Synthesis, characterization and antitumor activity of macromolecular prodrugs of adriamycin. Recent Advances in Drug Delivery Systems 1984, 77-100. Plenum, New York. J.M. Anderson, S.W. Kim (Eds.).
27. Volm M., Koomagi R., Mattern J., Stammler G. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relation shis to drug response in vitro. Anticancer Res. 1997, 17:99-103.
28. Xu M., Kumar D., Srinivas S., Detolla L.J., Yu S.F., Stass S.A., Mixson A.J. Parenteral gene therapy with p53 inhibits human breast tumor in vivo through a bystander mechanism without evidence of toxicity. Hum. Gene Ther. 1997, 8:177-185.
29. Zhang X., Collins L., Sawyer G.J., Dong X., Qiu Y., Fabre J.W. In vivo gene delivery via portal vein and bile duct to individual lobes of the rat liver using a polylysine-based nonviral DNA vector in combination with chloroquine. Hum. Gene Ther. 2001, 12:2179-2190.
30. Zou Y.Y., Ling Y.H., Van N.T., Priebe W., Perez-Soler R. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res. 1994, 54:1479-2148.